Partnering Opens April 15

INSIGHT    •    INTERACT    •    INVEST

Why attend Cancer Progress?

Gain insights from provocative, frank and visionary panel discussions-no boring speeches or sales pitches!

Learn about the import and impact of the latest advancements in cancer research and treatments for patients, companies and payers

Access leading oncology innovators, industry executives and investors through Cancer Progress Partnering

With your generosity and support, we are proud to announce that Cancer Progress donated $20,000 to cancer-related and COVID-19 first-line responder charitable organizations in 2020. We look forward to making a significant contribution to these causes again in 2021.

Thank you for your support!


Cello Health BioConsultingCello Health

Meet with Leading Companies and Institutions at Cancer Progress 2021

  • AbbVie Ventures (tentative)
  • Abintus Bio
  • Adaptive Biotechnologies Corp.
  • Adicet Therapeutics
  • ADVI Health
  • Affimed
  • Aleta Biotherapeutics
  • Alloplex Biotherapeutics
  • Amphivena Therapeutics Inc
  • Arsenal Capital Partners
  • Ascentage Pharma
  • Astellas
  • Atossa Therapeutics
  • Bayer
  • BeiGene
  • BioInvent International
  • BresMed
  • Caribou Biosciences, Inc.
  • Carisma Therapeutics Inc.
  • Cartherics
  • Cello Health BioConsulting
  • Clinical Accelerator and Venture Fund Cancer Research Institute
  • Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center
  • Compass Therapeutics
  • Crescendo Biologics Ltd
  • Cytovia Therapeutics
  • Dana-Farbe Cancer Institute
  • Fate Theraputics
  • Fred Hutchinson Cancer Center
  • F-star Biotech
  • Hillhouse Capital Management
  • I-Mab Biopharma
  • IGM Biosciences
  • Immatics
  • in8bio
  • IO Biotech
  • Ipsen
  • KAPital Consulting LLC
  • kuur
  • Leukemia & Lymphoma Society
  • Lilly Asia Ventures
  • Loxo Oncology at Lilly
  • Marker Therapeutic
  • MD Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Merck & Co., Inc
  • Merck and Co.
  • Nanobiotix
  • Nanostring Technology
  • National Foundation for Cancer Research
  • NCI
  • Notch Therapeutics
  • Obsidian Therapeutics, Inc.
  • Pfizer Inc.
  • Shattuck Labs, Inc.
  • Silverback Therapeutics
  • Sofinnova Investments
  • Spotlight Therapeutics
  • Stanford Comprehensive Cancer Institute, Stanford University
  • Strand Therapeutics
  • The Institute of Cancer Research
  • The University of Texas MD Anderson Cancer Center
  • Tminuty Therapeutics Inc
  • Torreya
  • Triumvera
  • University of Chicago
  • University of Colorado School of Medicine
  • Venture Investments, The Mark Foundation
  • Vertex Ventures
  • Vor Bio Pharm
  • WindMIL

Keynote Speaker Day One

Engineering the Future: Next Gen Platforms in Oncology

Daniel S. Chen, MD, PhD

Tuesday, May 4, 2021 | 9:15 – 10:00 am EDT

Chief Medical Officer

 

Keynote Speaker Day Two

Off-the-shelf CAR-engineered NK cells for the treatment of cancer

Katy Rezvani, MD, PhD

Wednesday, May 5, 2021 | 9:15 – 10:00 am EDT

Principal Investigator, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine

Cancer Progress Conference Panels Include...

Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors

Multifunctional Soluble Biologics: Binders, Binders Everywhere

Tumor Agnostic Development

Accelerated Development Paths

Endogenous Reprogramming: Anything One Can Do Ex Vivo, Can One Do In Vivo (and Do Better)?

Allogeneic Cell Therapy: Stocking the Shelf Part I (NKs, NKTs)

Allogeneic Cell Therapy: Stocking the Shelf Part II (Traditional T-cells, Gamma-deltas)

Cell Therapy in Solid Tumors: Freedom of the Open Road

Validating New Platforms: Clinical Pain, Commercial Gain

Counterpoint to Engineered Platforms: Less is More

Cross-border Dealmaking: China Importing/Exporting Trends and Challenges

Investing in the Emerald City of Oncology Innovation: Platforms & Modalities & Targets, Oh My!

Heme Malignancies Transformed: An Idiosyncratic Comparison of Multiple Myeloma and AML

Let’s Make a Deal in Oncology: What’s Behind the Doors & Who Has the Keys? Value Panel

Battle of the Modalities- The sequel

Cancer Progress 2020 Panel Summaries

As a preview of the good things to expect from Cancer Progress 2021, we’re excited to roll out summaries of select sessions from Cancer Progress 2020, starting with a summary of the panel “Paradigm Shifting Platforms II – Non-IO: Targeting Better, Targeting the Intractable” that highlights the key opportunities and challenges of non-IO targeted approaches and how even they cannot be thought of independently from IO.

 

Paradigm Shifting Platforms I –IO: Taking IO to the Next Level

Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable

Thank you to our Cancer Progress 2021 Sponsors

Platinum Partnering Sponsor
Gold Sonsors
Silver Sponsors
Bronze Sponsors
Partnership Sponsor

Testimonials

Good array of opinions and technologies. Well curated

Andrew Allen, MD, PhD, President & CEO

Gritstone Oncology

As I like to say, Cancer Progress is THE BEST non-academic cancer conference out there. Again proving your staggering insight!

Michael G. King, Jr., Entrepreneur in Residence

Fortress Biotech Inc.

When we hear all the negatives from the experts on cell therapies and COVID—let’s think of Richard Feynman: “Science is the belief in the ignorance of the experts

Mark Simon, Managing Director

Torreya

“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”

Noemi Rosa

Novartis

“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”

Richard Brian Gaynor, Sr. Vice President Global Development / Medical Affairs, Oncology Business Unit

Eli Lilly and Company